These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30820349)

  • 1. GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer.
    Perez-Fidalgo JA; Iglesias M; Bohn U; Calvo E; Garcia Y; Guerra E; Manso L; Santaballa A; Gonzalez-Martin A
    Future Sci OA; 2019 Feb; 5(2):FSO370. PubMed ID: 30820349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study).
    Perez-Fidalgo JA; Cortés A; Guerra E; García Y; Iglesias M; Bohn Sarmiento U; Calvo García E; Manso Sánchez L; Santaballa A; Oaknin A; Redondo A; Rubio MJ; González-Martín A
    ESMO Open; 2021 Aug; 6(4):100212. PubMed ID: 34329939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601.
    Perez-Fidalgo JA; Guerra E; García Y; Iglesias M; Hernández-Sosa M; Estevez-García P; Manso Sánchez L; Santaballa A; Oaknin A; Redondo A; Rubio MJ; González-Martín A
    Int J Gynecol Cancer; 2023 Jun; 33(6):929-936. PubMed ID: 36759001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
    Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
    J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
    Shoji T; Komiyama S; Kigawa J; Tanabe H; Kato K; Itamochi H; Fujiwara H; Kamiura S; Hamano T; Sugiyama T;
    BMC Cancer; 2018 Jul; 18(1):771. PubMed ID: 30064406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
    Poveda AM; Davidson R; Blakeley C; Milner A
    Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer.
    Park J; Cho HW; Lim MC; Choi CH; Lee JY
    Future Oncol; 2024; 20(26):1893-1899. PubMed ID: 38940373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study.
    Steffensen KD; Waldstrøm M; Pallisgård N; Lund B; Bergfeldt K; Wihl J; Keldsen N; Marth C; Vergote I; Jakobsen A
    Int J Gynecol Cancer; 2013 Jan; 23(1):73-80. PubMed ID: 23211422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
    Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD
    Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases.
    Anastasia A; Dellavedova G; Ramos-Montoya A; James N; Chiorino G; Russo M; Baakza H; Wilson J; Ghilardi C; Cadogan EB; Giavazzi R; Bani MR
    Mol Cancer Ther; 2022 Apr; 21(4):555-567. PubMed ID: 35149547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Pujade-Lauraine E; Ledermann JA; Selle F; Gebski V; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Friedlander M; Colombo N; Harter P; Fujiwara K; Ray-Coquard I; Banerjee S; Liu J; Lowe ES; Bloomfield R; Pautier P;
    Lancet Oncol; 2017 Sep; 18(9):1274-1284. PubMed ID: 28754483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.
    Marth C; Vergote I; Scambia G; Oberaigner W; Clamp A; Berger R; Kurzeder C; Colombo N; Vuylsteke P; Lorusso D; Hall M; Renard V; Pignata S; Kristeleit R; Altintas S; Rustin G; Wenham RM; Mirza MR; Fong PC; Oza A; Monk BJ; Ma H; Vogl FD; Bach BA
    Eur J Cancer; 2017 Jan; 70():111-121. PubMed ID: 27914241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
    Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
    Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of recurrent ovarian cancer.
    Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
    Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial.
    Herzog TJ; Kutarska E; Bidzińsk M; Symanowski J; Nguyen B; Rangwala RA; Naumann RW
    Int J Gynecol Cancer; 2016 Nov; 26(9):1580-1585. PubMed ID: 27654255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
    Ray-Coquard I; Pautier P; Pignata S; Pérol D; González-Martín A; Berger R; Fujiwara K; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alía EM; Reinthaller A; Nagao S; Lefeuvre-Plesse C; Canzler U; Scambia G; Lortholary A; Marmé F; Combe P; de Gregorio N; Rodrigues M; Buderath P; Dubot C; Burges A; You B; Pujade-Lauraine E; Harter P;
    N Engl J Med; 2019 Dec; 381(25):2416-2428. PubMed ID: 31851799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
    del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
    Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
    Emons G; Gorchev G; Sehouli J; Wimberger P; Stähle A; Hanker L; Hilpert F; Sindermann H; Gründker C; Harter P
    Gynecol Oncol; 2014 Jun; 133(3):427-32. PubMed ID: 24713545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.